A Multi-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Anakinra (Primary) ; Tocilizumab (Primary)
- Indications COVID 2019 infections; Respiratory distress syndrome
- Focus Therapeutic Use
- Acronyms ImmCoVA
- 30 May 2021 This trial has been completed in Sweden (Global end date: 17 May 2021).
- 07 Sep 2020 New trial record